PHP5 DOES ENTRY OF GENERIC DRUGS ALWAYS RESULT IN COST-CONTAINMENT? THE HUNGARIAN EVIDENCE  by Kalo, Z et al.
products from Canadian on-line pharmacies during a 180-day
exclusivity period. A decrease of U.S. generic prices is expected
following this period as more products enter the market, and U.S.
prices over time typically fall below those of Canadian generic
prices. The availability of Canadian drugs to U.S. residents
increases the short-run competition to independent and autho-
rized generic companies during exclusivity periods.
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OBJECTIVES: Patent protection is the key condition of phar-
maceutical innovation. After patent expiry utilisation of generic
drugs decreases health care expenditure, and alleviates the scar-
city of health care budget. Our objective was to measure the
ability of generics to reduce the pharmaceutical expenditure in
the Hungarian market. METHODS: Drug utilisation records of
10 substances with patent expiry between 2001–2006 have
been compared 12 months before and after the entry of the ﬁrst
generic product. RESULTS: Although entry of generics reduced
daily therapeutic costs, the increase in volume sales outbal-
anced the potential savings in drug budget. Overall generic
drugs increased the expenditure of a subtance with no patent
protection by 30.1%, the public reimbursement by 25.7%, and
unit sales by 21.0%. In 5 cases the originator successfully con-
verted the majority of patients to a non-substitutable formula-
tion. When we limited our analysis to substances with no
restrictions in generic substitution, public reimbursement and
unit sales were still increased by 21.1%, 17.4% and 18.6%
respectively. CONCLUSION: The entry of generic drugs in
Hungary—as opposed to the international experience—did not
reduce pharmaceutical expenditure between 2001–2006, what
is more, generics increased the tendency of pharmaceutical
spending. The main reason for this failure was the inappropri-
ate generic drug policy. The lack of delisting, the low generic
price erosion, the lack of incentives to physicians and phar-
macists to switch patients to generic products, the branded
promotional campaigns by generic manufacturers, and the con-
version of patients to patented formulations by original manu-
facturers contributed to the inefﬁciency of the generic
programme in Hungary.
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OBJECTIVES: Policymakers increasingly use a policy of “condi-
tional reimbursement” of pharmaceutical care in order to obtain
more control over drug prescriptions and increase patient, phy-
sician and payer compliance to drug use. Our objective was to
resolve which factors determine the efﬁcient functioning of con-
ditional reimbursement as a policy-tool. METHODS: Drawing
on 65 interviews and two focus-group sessions with representa-
tives of patients, physicians, pharmacists, health insurers, phar-
maceutical industry, and policymakers, we studied stakeholders’
perspectives on the general functioning of conditional reimburse-
ment as a policy tool, with particular attention being paid to ﬁve
drugs. The participants’ data was completed and validated by
way of document analysis. RESULTS: Effectiveness of condi-
tional reimbursement depends on how it has been implemented
and/or how stringently regulations are enforced. The data
revealed controversies concerning the policy-tool’s transparency,
legitimacy, feasibility and commitment on the part of the stake-
holders. These controversies most often were caused by a lack of
coordination and cooperation within the network of drug reim-
bursement. Yet, a good network in which coordination and coop-
eration are facilitated appeared a necessary, but sometimes not
sufﬁcient condition. Case-speciﬁc characteristics have the poten-
tial to make or break the networks in which the instrument is
embedded and often are beyond control of the policymakers.
CONCLUSION: Problems occur when the conditional reim-
bursement policy fails to connect to the range of diverse interests
of those carrying the instrument to its effect. Conditional reim-
bursement has the potential to work if a more or less stable
network, in which cooperation and coordination are organized,
is available or can be created. Moreover, policymakers should
take into account whether case-speciﬁc characteristics will ﬁt into
or frustrate the network. If both prerequisites are available/
positive the instrument will more likely be found to be legitimate
and transparent, and consequently the compliance by its users
will rise.
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OBJECTIVES: The introduction of generic price-regulated
systems in many European countries, the trend towards interna-
tional generic medicine companies, and competition from Indian
companies emphasise the need to gain insight into international
prices of generic medicines. The aim of this study is to compare
generic medicine prices in ambulatory care in Belgium with prices
in other countries in 2005. The price difference between original
and generic medicines in Belgium is also elicited. METHODS:
Data on ex-manufacturer prices of generic medicines of 15
molecules/strengths were derived from IMS Health. Belgian
prices were compared with prices observed in Denmark, France,
Germany, India, The Netherlands, Norway, Spain, Sweden and
the UK. Comparability of pharmaceutical form was attained by
limiting the analysis to medicines in immediate-release, oral,
solid dosage forms. For each molecule/strength, the average price
per standard unit weighted by volume of sales of all available
package sizes and generic manufacturers was calculated.
RESULTS: India and Scandinavian countries had the lowest
ex-manufacturer prices of generic medicines of selected
molecules/strengths. The 15 molecules/strengths were, on
average, 63% cheaper in India than in Belgium. The average
price across generic molecules/strengths in Belgium (0.206 €) was
higher than the mean price across all countries (0.190 €). The
highest average price levels were observed in France (0.254 €),
The Netherlands (0.260 €) and Germany (0.269 €). Ex-
manufacturer prices of a speciﬁc generic molecule/strength varied
between countries by a factor 3–36, depending on the molecule/
strength. The price difference between original and generic
medicines generally ranged from -12% for simvastatin 20 mg
to -62% for enalapril 5 mg in Belgium. CONCLUSION:
Ex-manufacturer prices of selected generic medicines varied sub-
stantially between countries. India has emerged as a low-cost
producer of generic medicines. The international price compari-
son reveals that there may be scope for reducing generic medicine
prices in a number of countries.
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